
## **Supplementary Materials**


## High-resolution 3D visualization of nanomedicine distribution in tumours

Jennifer I. Moss et al.


Figure S1. Representative whole tumor sections showing IHC staining for CD31 (top) and  $\alpha$ SMA (bottom).


Suppl. Fig. 1A: Representative CD31 (top) and  $\alpha$ SMA (bottom) IHC staining on whole tumor section of Calu-6 tumor.






Suppl. Fig. 1B: Representative CD31 (top) and  $\alpha$ SMA (bottom) IHC staining on whole tumor section of Calu-3 tumor.






Suppl. Fig. 1C: Representative CD31 (top) and  $\alpha$ SMA (bottom) IHC staining on whole tumor section of E35CR tumor.

CD31




## $\alpha \text{SMA}$



3mm

Suppl. Fig. 1D: Representative CD31 (top) and  $\alpha$ SMA (bottom) IHC staining on whole tumor section of E77 tumor.







Figure S2. Lack of  $\mu$ CT enhancement in tumor at 30 minutes post-IV (A) and post-ITu (B) administration of free iohexol.

Suppl. Fig. 2A: Calu-6 tumor at 30 mins post-ITu dose of free iohexol.



Suppl. Fig. 2B: Calu-6 tumor at 30 mins post-IV dose of free iohexol.




Figure S3. Rotating 3D visualization of liposomes in H358 tumor post-ITu dosing.

